Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Maruho, Tsukuba Startup Ink ALDH2 Activator Deal
July 4, 2023
- 32 Pharma Execs Take Home Over 100 Million Yen in FY2022, Top 3 from Takeda: Securities Reports
July 3, 2023
- Meiji Seeks Booster Nod for COVID-19 mRNA Vaccine in Japan
July 3, 2023
- AstraZeneca Exits PhRMA in Japan after Global Decision
July 3, 2023
- Eisai Transfers Economic Rights for Breast Cancer Med to DRI
July 3, 2023
- Takeda Files Acquired Hemophilia A Therapy in Japan
July 3, 2023
- Shionogi’s Mulpleta Approved in China
July 3, 2023
- Taisho Launches 2nd Voluntary Redundancy Program
June 30, 2023
- Pfizer Japan Files BCMA Bispecific Elranatamab for MM
June 30, 2023
- CAR-T Player Noile-Immune Goes Public on TSE
June 30, 2023
- Shionogi Launches PIII Pediatric Study for Xocova in Japan
June 30, 2023
- Takeda CEO Touts Aggressive Dividend Policy as Deleveraging Drive Hits Goal
June 29, 2023
- Chugai Trims 150 Reps via Voluntary Buyout, Sales Force Down to 1,050 from July
June 29, 2023
- Astellas’ Hot Flash Med Nets Positive PIIIb Results in Europe
June 29, 2023
- Takeda CEO Earns 1.72 Billion Yen in FY2022, Down 135 Million Yen
June 29, 2023
- Keytruda Label Updated to Add Hodgkin Lymphoma Data
June 28, 2023
- UN-Backed Agency, 7 Firms Ink Deals for Generic Supply of Shionogi’s COVID Pill to LMICs
June 28, 2023
- Taiho, Kyushu University in Research Tie-Up on Covalent Reactive Groups
June 28, 2023
- Meiji Seika Pharma Files GVHD Drug Belumosudil in Japan
June 28, 2023
- UCB Japan Seeks Lennox-Gastaut Syndrome Indication for Fintepla
June 28, 2023
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…